The peptide does not produce significant spikes in lactate or contribute to elevated stress hormones, which makes it suitable for long-term or high-frequency study designs. Researchers can gather extended data sets without confounding variables caused by hormonal stress.

MK-677, is a orally bio-active, selective agonist of the ghrelin receptor. Research shows that MK-677 increases the natural secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), but does not affect cortisol levels. It is being researched as a possible treatment for GH deficiency, muscle and bone wasting, appetite stimulation and Alzheimer's disease. MK-677 research in mice, appeared to prevent the onset of AD, even in genetically predisposed mice, as long as it was started before significant amyloid beta accumulation. MK-677 research has also shown exceptionally promising benefits in improving sleep quality.

PT-141, also called Bremelanotide (generic clinical name), is a heavily modified synthetic derivative of alpha-melanocyte-stimulating hormone. It has been tested in clinical trials as a treatment for both male/female hypoactive sexual desire disorder and acute hemorrhage. PT-141 is an agonist for the melanocortin-4 and melanocortin-1 receptors. Research shows that it promotes sexual arousal and stimulates the immune system.

Tesamorelin’s growing body of evidence highlights its significance not only for HIV-associated lipodystrophy but for broader metabolic research. Its targeted effects, safety profile, and hormonal precision make it a cornerstone peptide in modern endocrinology and metabolic science.